|
1
|
Ai J, Li J, Gessler DJ, Su Q, Wei Q, Li H
and Gao G: Adeno-associated virus serotype rh.10 displays strong
muscle tropism following intraperitoneal delivery. Sci Rep.
7:403362017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang D, Zhong L, Nahid MA and Gao G: The
potential of adeno-associated viral vectors for gene delivery to
muscle tissue. Expert Opin Drug Deliv. 11:345–364. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Dismuke DJ, Tenenbaum L and Samulski RJ:
Biosafety of recombinant adeno-associated virus vectors. Curr Gene
Ther. 13:434–452. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lotfinia M, Abdollahpour-Alitappeh M,
Hatami B, Zali MR and Karimipoor M: Adeno-associated virus as a
gene therapy vector: Strategies to neutralize the neutralizing
antibodies. Clin Exp Med. 19:289–298. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vercauteren K, Hoffman BE, Zolotukhin I,
Keeler GD, Xiao JW, Basner-Tschakarjan E, High KA, Ertl HC, Rice
CM, Srivastava A, et al: Superior in vivo transduction of human
hepatocytes using engineered AAV3 capsid. Mol Ther. 24:1042–1049.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang L, Bell P, Somanathan S, Wang Q, He
Z, Yu H, McMenamin D, Goode T, Calcedo R and Wilson JM: Comparative
study of liver gene transfer with AAV vectors based on natural and
engineered AAV capsids. Mol Ther. 23:1877–1887. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Naso MF, Tomkowicz B, Perry WL and Strohl
WR: Adeno-Associated Virus (AAV) as a vector for gene therapy.
BioDrugs. 31:317–334. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bates R, Huang W and Cao L: Adipose
tissue: An emerging target for adeno-associated viral vectors. Mol
Ther Methods Clin Dev. 19:236–249. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mushimiyimana I, Niskanen H, Beter M,
Laakkonen JP, Kaikkonen MU, Ylä-Herttuala S and Laham-Karam N:
Characterization of a functional endothelial super-enhancer that
regulates ADAMTS18 and angiogenesis. Nucleic Acids Res.
49:8078–8096. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pham PL, Kamen A and Durocher Y:
Large-scale transfection of mammalian cells for the fast production
of recombinant protein. Mol Biotechnol. 34:225–237. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Powell SK, Rivera-Soto R and Gray SJ:
Viral expression cassette elements to enhance transgene target
specificity and expression in gene therapy. Discov Med. 19:49–57.
2015.PubMed/NCBI
|
|
12
|
Lee LR, Peacock L, Lisowski L, Little DG,
Munns CF and Schindeler A: Targeting Adeno-Associated Virus vectors
for local delivery to fractures and systemic delivery to the
skeleton. Mol Ther Methods Clin Dev. 15:101–111. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Daly TM, Okuyama T, Vogler C, Haskins ME,
Muzyczka N and Sands MS: Neonatal intramuscular injection with
recombinant adeno-associated virus results in prolonged
beta-glucuronidase expression in situ and correction of liver
pathology in mucopolysaccharidosis type VII mice. Hum Gene Ther.
10:85–94. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kosuga M, Enosawa S, Li XK, Suzuki S,
Matsuo N, Yamada M, Roy-Chowdhury J, Koiwai O and Okuyama T:
Strong, long-term transgene expression in rat liver using chicken
beta-actin promoter associated with cytomegalovirus immediate-early
enhancer (CAG promoter). Cell Transplant. 9:675–680. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen SJ, Sanmiguel J, Lock M, McMenamin D,
Draper C, Limberis MP, Kassim SH, Somanathan S, Bell P, Johnston
JC, et al: Biodistribution of AAV8 vectors expressing human
low-density lipoprotein receptor in a mouse model of homozygous
familial hypercholesterolemia. Hum Gene Ther Clin Dev. 24:154–160.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yan Z, Yan H and Ou H: Human thyroxine
binding globulin (TBG) promoter directs efficient and sustaining
transgene expression in liver-specific pattern. Gene. 506:289–294.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Z, Zhu T, Rehman KK, Bertera S, Zhang
J, Chen C, Papworth G, Watkins S, Trucco M, Robbins PD and Xiao X:
Widespread and stable pancreatic gene transfer by adeno-associated
virus vectors via different routes. Diabetes. 55:875–884. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sobrevals L, Enguita M, Rodriguez C,
Gonzalez-Rojas J, Alzaguren P, Razquin N, Prieto J and Fortes P:
AAV vectors transduce hepatocytes in vivo as efficiently in
cirrhotic as in healthy rat livers. Gene Ther. 19:411–417. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cunningham SC, Dane AP, Spinoulas A and
Alexander IE: Gene delivery to the juvenile mouse liver using
AAV2/8 vectors. Mol Ther. 16:1081–1088. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu G, Dai M, Zheng X, Lin H, Liu A and
Yang J: Cholestatic models induced by lithocholic acid and
α-naphthylisothiocyanate: Different etiological mechanisms for
liver injury but shared JNK/STAT3 signaling. Mol Med Rep.
22:1583–1593. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Niwa H, Yamamura K and Miyazaki J:
Efficient selection for high-expression transfectants with a novel
eukaryotic vector. Gene. 108:193–199. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Buck TM and Wijnholds J: Recombinant
Adeno-Associated Viral Vectors (rAAV)-vector elements in ocular
gene therapy clinical trials and transgene expression and
bioactivity assays. Int J Mol Sci. 21:41972020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Acland GM, Aguirre GD, Bennett J, Aleman
TS, Cideciyan AV, Bennicelli J, Dejneka NS, Pearce-Kelling SE,
Maguire AM, Palczewski K, et al: Long-term restoration of rod and
cone vision by single dose rAAV-mediated gene transfer to the
retina in a canine model of childhood blindness. Mol Ther.
12:1072–1082. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gardiner KL, Cideciyan AV, Swider M,
Dufour VL, Sumaroka A, Komáromy AM, Hauswirth WW, Iwabe S, Jacobson
SG, Beltran WA and Aguirre GD: Long-term structural outcomes of
late-stage RPE65 gene therapy. Mol Ther. 28:266–278. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carrillo-Carrasco N, Chandler RJ,
Chandrasekaran S and Venditti CP: Liver-directed recombinant
adeno-associated viral gene delivery rescues a lethal mouse model
of methylmalonic acidemia and provides long-term phenotypic
correction. Hum Gene Ther. 21:1147–1154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Baruteau J, Waddington SN, Alexander IE
and Gissen P: Gene therapy for monogenic liver diseases: Clinical
successes, current challenges and future prospects. J Inherit Metab
Dis. 40:497–517. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Erokhin M, Vassetzky Y, Georgiev P and
Chetverina D: Eukaryotic enhancers: Common features, regulation,
and participation in diseases. Cell Mol Life Sci. 72:2361–2375.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Greig JA, Nordin JM, Bote E, Makaron L,
Garnett ME, Kattenhorn LM, Bell P, Goode T and Wilson JM: Impact of
intravenous infusion time on AAV8 vector pharmacokinetics, safety,
and liver transduction in cynomolgus macaques. Mol Ther Methods
Clin Dev. 3:160792016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chen BD, He CH, Chen XC, Pan S, Liu F, Ma
X, Li XM, Gai MT, Tao J, Ma YT, et al: Targeting transgene to the
heart and liver with AAV9 by different promoters. Clin Exp
Pharmacol Physiol. 42:1108–1117. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Dalwadi DA, Torrens L, Abril-Fornaguera J,
Pinyol R, Willoughby C, Posey J, Llovet JM, Lanciault C, Russell
DW, Grompe M and Naugler WE: Liver injury increases the incidence
of HCC following AAV gene therapy in mice. Mol Ther. 29:680–690.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yu DL, Chow N and Wootton SK: JSRV
intragenic enhancer element increases expression from a
heterologous promoter and promotes high level AAV-mediated
transgene expression in the lung and liver of mice. Viruses.
12:12662020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li S, Ling C, Zhong L, Li M, Su Q, He R,
Tang Q, Greiner DL, Shultz LD, Brehm MA, et al: Efficient and
targeted transduction of nonhuman primate liver with systemically
delivered optimized AAV3B vectors. Mol Ther. 23:1867–1876. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Greig JA, Calcedo R, Kuri-Cervantes L,
Nordin JM, Albrecht J, Bote E, Goode T, Chroscinski EA, Bell P,
Richman LK, et al: AAV8 gene therapy for crigler-najjar syndrome in
macaques elicited transgene T Cell responses that are resident to
the liver. Mol Ther Methods Clin Dev. 11:191–201. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sabatino DE, Lange AM, Altynova ES, Sarkar
R, Zhou S, Merricks EP, Franck HG, Nichols TC, Arruda VR and
Kazazian HH: Efficacy and safety of long-term prophylaxis in severe
hemophilia A dogs following liver gene therapy using AAV vectors.
Mol Ther. 19:442–449. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chandler RJ, LaFave MC, Varshney GK,
Trivedi NS, Carrillo-Carrasco N, Senac JS, Wu W, Hoffmann V,
Elkahloun AG, Burgess SM and Venditti CP: Vector design influences
hepatic genotoxicity after adeno-associated virus gene therapy. J
Clin Invest. 125:870–880. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nault JC, Datta S, Imbeaud S, Franconi A,
Mallet M, Couchy G, Letouzé E, Pilati C, Verret B, Blanc JF, et al:
Recurrent AAV2-related insertional mutagenesis in human
hepatocellular carcinomas. Nat Genet. 47:1187–1193. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang PR, Xu M, Toffanin S, Li Y, Llovet JM
and Russell DW: Induction of hepatocellular carcinoma by in vivo
gene targeting. Proc Natl Acad Sci USA. 109:11264–11269. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Smith JS, Tian J, Muller J and Byrnes AP:
Unexpected pulmonary uptake of adenovirus vectors in animals with
chronic liver disease. Gene Ther. 11:431–438. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hinderer C, Katz N, Buza EL, Dyer C, Goode
T, Bell P, Richman LK and Wilson JM: Severe toxicity in nonhuman
primates and piglets following high-dose intravenous administration
of an adeno-associated virus vector expressing human SMN. Hum Gene
Ther. 29:285–298. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mendell JR, Al-Zaidy S, Shell R, Arnold
WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church
K, et al: Single-dose gene-replacement therapy for spinal muscular
atrophy. N Engl J Med. 377:1713–1722. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ginocchio VM, Ferla R, Auricchio A and
Brunetti-Pierri N: Current status on clinical development of
adeno-associated virus-mediated liver-directed gene therapy for
inborn errors of metabolism. Hum Gene Ther. 30:1204–1210. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Grimm D and Büning H: Small but
increasingly mighty: Latest advances in AAV vector research,
design, and evolution. Hum Gene Ther. 28:1075–1086. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kattenhorn LM, Tipper CH, Stoica L,
Geraghty DS, Wright TL, Clark KR and Wadsworth SC: Adeno-associated
virus gene therapy for liver disease. Hum Gene Ther. 27:947–961.
2016. View Article : Google Scholar : PubMed/NCBI
|
